The clinical benefit rate was 59.4%, with one participant achieving a partial response and 18 showing stable disease.

Novel combination with efti has met the trial's primary endpoint of tumour hyalinization/fibrosis in the neoadjuvant setting ...

The liposarcoma pipeline report provides detailed profiles of pipeline assets, a comparative analysis of clinical and non-clinical stage liposarcoma drugs, inactive and dormant assets, a comprehensive ...

SPECIALIST vets have been credited with saving the life of a much-loved pet pooch after he underwent daily radiotherapy ...

Immutep’s efti with radiotherapy and pembrolizumab meets primary endpoint in phase II trials for soft tissue sarcoma ...

Novel combination with efti has met the trial's primary endpoint of tumour hyalinization/fibrosis in the neoadjuvant setting ...